Menu Search
Equities

Exscientia PLC

0RK:DEU

Exscientia PLC

Actions
  • Price (EUR)4.70
  • Today's Change0.12 / 2.62%
  • Shares traded16.64k
  • 1 Year change+8.80%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Precision Target, Precision Design, Precision Experiment, Precision Medicine, Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.

  • Revenue in USD (TTM)25.16m
  • Net income in USD-182.91m
  • Incorporated2021
  • Employees483.00
  • Location
    Exscientia PLCThe Schrodinger BuildingOxford Science ParkOXFORD OX4 4GEUnited KingdomGBR
  • Phone+44 186 581 8941
  • Websitehttps://www.exscientia.ai/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.